Osteoporosis in 2022: care gaps to screening and personalised medicine
Osteoporosis in 2022: care gaps to screening and personalised medicine
Osteoporosis care has evolved markedly over the last 50 years, such that there are now an established clinical definition, validated methods of fracture risk assessment, and a range of effective pharmacological agents. However, it is apparent that both in the context of primary and secondary fracture prevention, there is a considerable gap between the population at high fracture risk and those actually receiving appropriate antiosteoporosis treatment. In this narrative review article, we document recent work describing the burden of disease, approaches to management, and service provision across Europe, emerging data on gaps in care, and existing/new ways in which these gaps may be addressed at the level of healthcare systems and policy. We conclude that although the field has come a long way in recent decades, there is still a long way to go, and a concerted, integrated effort is now required from all of us involved in this field to address these urgent issues to ensure the best possible outcomes for our patients.
Epidemiology, Fracture, Osteoporosis, Policy, Treatment gap
Curtis, Elizabeth
12aba0c3-1e9e-49ef-a7e9-3247e649cdd6
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Harvey, Nicholas
ce487fb4-d360-4aac-9d17-9466d6cba145
September 2022
Curtis, Elizabeth
12aba0c3-1e9e-49ef-a7e9-3247e649cdd6
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Harvey, Nicholas
ce487fb4-d360-4aac-9d17-9466d6cba145
Curtis, Elizabeth, Dennison, Elaine, Cooper, Cyrus and Harvey, Nicholas
(2022)
Osteoporosis in 2022: care gaps to screening and personalised medicine.
Best Practice and Research Clinical Rheumatology, 36 (3), [101754].
(doi:10.1016/j.berh.2022.101754).
Abstract
Osteoporosis care has evolved markedly over the last 50 years, such that there are now an established clinical definition, validated methods of fracture risk assessment, and a range of effective pharmacological agents. However, it is apparent that both in the context of primary and secondary fracture prevention, there is a considerable gap between the population at high fracture risk and those actually receiving appropriate antiosteoporosis treatment. In this narrative review article, we document recent work describing the burden of disease, approaches to management, and service provision across Europe, emerging data on gaps in care, and existing/new ways in which these gaps may be addressed at the level of healthcare systems and policy. We conclude that although the field has come a long way in recent decades, there is still a long way to go, and a concerted, integrated effort is now required from all of us involved in this field to address these urgent issues to ensure the best possible outcomes for our patients.
Text
nch OP gaps BPM 2022_03_29 clean
- Accepted Manuscript
Text
1-s2.0-S1521694222000134-main (1)
- Proof
More information
Accepted/In Press date: 1 June 2022
e-pub ahead of print date: 9 June 2022
Published date: September 2022
Additional Information:
Funding Information:
We would like to thank the UK Medical Research Council (MC_PC_21003; MC_PC_21001), UK Medical Research Foundation (MRF-145-0011-DG-HARV-C0913), National Institute for Health Research , Wellcome Trust , Versus Arthritis , Royal Osteoporosis Society Osteoporosis and Bone Research Academy and International Osteoporosis Foundation for supporting this work. This article includes text reproduced/adapted, with permission from Refs. [ 1 , 2 , 5 , 8 , 63 , 73 , 94 ].
Funding Information:
EC reports honoraria/travel support from Eli Lilly, UCB and Amgen outside the submitted work. EMD reports no conflicts of interest. CC reports personal fees from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work. NCH reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare, UCB, Kyowa Kirin and Internis Pharma, outside the submitted work.We would like to thank the UK Medical Research Council (MC_PC_21003; MC_PC_21001), UK Medical Research Foundation (MRF-145-0011-DG-HARV-C0913), National Institute for Health Research, Wellcome Trust, Versus Arthritis, Royal Osteoporosis Society Osteoporosis and Bone Research Academy and International Osteoporosis Foundation for supporting this work. This article includes text reproduced/adapted, with permission from Refs. [1,2,5,8,63,73,94].
Publisher Copyright:
© 2022 The Author(s)
Keywords:
Epidemiology, Fracture, Osteoporosis, Policy, Treatment gap
Identifiers
Local EPrints ID: 466878
URI: http://eprints.soton.ac.uk/id/eprint/466878
ISSN: 0307-742X
PURE UUID: 831a2311-c6be-4eb8-93f0-4b1d97bb5603
Catalogue record
Date deposited: 05 Jul 2022 07:02
Last modified: 18 Mar 2024 03:38
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
